Pressure BioSciences Announces Initial Close of $610,000 in

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 14, 2016 at 9:30 AM

Pressure BioSciences Announces Initial Close of $610,000 in $2.5 Million Private Placement

SOUTH EASTON, MA--(Marketwired - Nov 14, 2016) - Pressure BioSciences, Inc. ( OTCQB : PBIO ) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure-based sample preparation solutions to the worldwide life sciences industry, led by their patented pressure cycling technology ("PCT") platform, today announced the initial close of $610,000 in gross proceeds in a $2.5 Million Private Placement (the "Financing"). Three accredited investors participated in the Financing. All investments were made in cash and were received into escrow between August 29 and November 10, 2016. One or more additional closes in the Financing are expected to occur in the near future.

Pursuant to the Subscription Agreement, the Company issued 1,525,000 shares of restricted common stock at $0.40 per share and Common Stock Purchase Warrants exercisable into a total of 1,525,000 shares of restricted common stock at $0.50 per share. There are no registration rights with respect to the shares of common stock or the shares underlying the Common Stock Purchase Warrants issued in the Financing. The Company received net proceeds of $512,750 after subtracting legal and placement agent fees related to the Financing.

This press release is not an offer to sell or a solicitation of offers to participate in the Financing. The restricted Common Stock and the shares underlying the Warrants have not been registered under the Securities Act and may not be sold in the United States absent registration under the Securities Act or an applicable exemption from registration.

About Pressure BioSciences, Inc. Pressure BioSciences, Inc. ("PBI") ( OTCQB : PBIO ) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

Forward Looking Statements Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, in the Company's Quarterly Report on Form 10-Q for the periods ended March 31 and June 30, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, Twitter, and Investors Hangout: http://investorshangout.com/

Investor Contacts: Richard T. Schumacher President & CEO (508) 230-1828 (T) Jeffrey N. Peterson Chairman (650) 812-8121 (T)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sempra Shines with Robust Q3 2026 Financials

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Co-Diagnostics Moves Up Q3 Earnings Release to Nov. 10

Co-Diagnostics Shifts Its Calendar Well, well, well, Co-Diagnostics decided to shake up its calendar. What are they looking to spill before the weekend? They’ve bumped up their third quarter 2026 earnings release by two days—an eyebrow-raiser for folks watching NASDAQ:CODX. Now they'll lay it all out on November 10, after we wrap up the trading day. I don’t want to...

FX's Game-Changer: Stemless Reverse Shoulder System

Stirring Up the Shoulder Market You gotta hand it to FX Shoulder Solutions – they've managed to elbow their way into the medical device market with something truly revolutionary. With the FDA clearance of Easytech Reversed®, a stemless reverse shoulder arthroplasty system, they're not just playing the innovation game; they're setting a whole new rulebook. This isn't...

Utility Returns: Short-Term Savings, Long-Term Costs

Crunching the Numbers on Utility Returns There's a buzz in the utility sector, and it's not just the hum of power lines—it’s all about return on equity (ROE). Concentric Energy Advisors just dropped some insights that could have us rethinking how these returns play into customer bills and utilities' financing capabilities. What's the Deal with ROE? Think of ROE like a...

Pink Bows Drives Crowd Safety with Global Initiative

Five years post-tragedy, and Madison Dubiski's memory still echoes fiercely in the halls of event safety. The Pink Bows Foundation, built out of heartache and resolve, is paving the way for safer gatherings worldwide. A sound move if there ever was one, as the chaotic Astroworld Festival proved we need it. Pushing Event Safety Boundaries Pink Bows isn't just sitting on...

JT Mega Embraces New Leadership as Erin Denham Steps Up

A New Captain at the Helm Erin Denham's promotion to president of JT Mega is setting the stage for some fresh momentum in the food and beverage advertising world. This Minnesotan agency, nestled right there on Minnetonka Boulevard, has been an independent force for five decades. It's a sector dominated by players who often get absorbed by the behemoth holding companies,...

Chesapeake Utilities Q3 2026: Growth Meets Strategy

Chesapeake Utilities Shows Strong Q3 2026 Growth Chesapeake Utilities Corporation (NYSE: CPK) ain't pulling any punches this quarter. They're showing off some solid numbers, with net income for Q3 hitting $21.6 million and EPS coming in at $0.89. Not just stopping there, these fellas are flexing a year-to-date growth rate of 8.4% on Adjusted EPS. Now, you gotta pay...

Nuvo's INVU™ Trial Reveals Boost in Fetal Monitoring

Remote Fetal Monitoring: A Game Changer in Prenatal Care? In the world of high-risk pregnancies, routine checkups aren't just a suggestion—they're vital. But when the logistics of shuttling back and forth to clinics get tangled with everyday life, something's gotta give. Enter Nuvo's INVU™. The REACTIVE trial, a Penn Medicine-led event funded by the NIH, aimed to see...

SensAI Veritas Unveils New Risk Intelligence Tools

Transforming Security Assessments with SensAI Security screenings are about to get a serious upgrade with SensAI Veritas rolling out their latest toys—the SensAI Gateway™ and Helm™. Forget what you knew about traditional identity checks; this is all about diving deeper to sniff out those hidden risks before anyone gets a green light. From Static Checks to Dynamic...

Aries Ignites a Social Renaissance in La Jolla

The Dawn of Aries: A Beacon for Social Change Coming out of nowhere, Aries is set to make waves in La Jolla, and no, I'm not talking about another swell hitting the shores. Instead, we're witnessing a new chapter for the rooftop of Hotel La Jolla, where an investment of over a cool million bucks aims to deliver a slice of European flare right here on the Pacific. A...